Skip to main content Skip to main navigation menu Skip to site footer

Efektifitas dan keamanan dari terapi kombinasi methotrexate dan secukinumab pada Psoriasis vulgaris berat: tinjauan sistematis



Abstract

Introduction: Psoriasis is a chronic inflammatory disease of the skin that requires comprehensive treatment. Combination therapy can be a good option in optimizing psoriasis treatment outcomes. However, the effectiveness and safety of combination therapy are still not fully understood. This study reviewed the literature examining the effectiveness and safety of the combination treatment of secukinumab and methotrexate in patients with severe Psoriasis vulgaris.

Methods: A literature search was performed on PubMed and Google Scholar databases, with several inclusion criteria. The research method used is a case report and controlled trial, with the critical appraisal method using the JBI Critical Appraisal.

Result: There were 6 pieces of literature that met the inclusion criteria. All literature describes in detail the clinical condition, course of the disease, management and side effects of treatment, but supporting examinations are not specifically described. In general, all literature shows a clinical improvement in severe psoriasis patients who are given combination treatment, and some literature also explains systemic side effects and residual plaque. The combination of biological agents with conventional systemic treatment has been proposed to optimize the results of psoriasis treatment. One study reported lightweight gastrointestinal disorders related to the use of a combination of secukinumab and methotrexate administration along with biological agents that could prevent or reduce the development of anti-drug antibodies and increase response levels to treatment. Advanced research is still needed in assessing this specific mechanism for this combination therapy

Conclusion: Combination therapy of secukinumab and methotrexate is effective in treating psoriasis skin manifestations without significant side effects. This drug combination is useful in overcoming the limitations of monotherapy drugs, such as decreasing effectiveness due to prolonged use.

 

Pendahuluan: Psoriasis merupakan penyakit inflamasi kronik pada kulit yang membutuhkan penanganan yang baik. Terapi kombinasi  dapat menjadi pilihan yang baik dalam mengoptimalkan luaran pengobatan psoriasis. Namun, efektifitas dan keamanan terapi kombinasi masih belum dipahami sepenuhnya dan masih harus di pertimbangkan. Studi ini menilai beberapa literatur yang menguji efektifitas dan keamanan dari pengobatan kombinasi secukinumab dan methotrexate pada pasien dengan Psoriasis vulgaris berat.

Metode: Pencarian literatur dilakukan pada database PubMed dan Google Scholar, dengan beberapa kriteria inklusi. Metode penelitian yang digunakan adalah case report dan controlled trial, dengan metode critical appraisal menggunakan JBI Critical Appraisal.

Hasil: Didapatkan sebanyak 6 literatur yang memenuhi kriteria inklusi. Semua literatur menjelaskan secara detail terkait kondisi klinis, perjalanan penyakit, tatalaksana dan efek samping pengobatan, namun pemeriksaaan penunjang tidak dijelaskan secara spesifik. Secara umum, semua literatur menunjukan adanya perbaikan klinis pada pasien psoriasis berat yang diberikan pengobatan kombinasi, beberapa literatur juga menjelaskan efek samping sistemik dan plak residu. Terapi kombinasi agen biologis dengan pengobatan sistemik konvensional telah diusulkan untuk mengoptimalkan hasil pengobatan psoriasis. Satu studi melaporkan adanya gangguan gastrointestinal ringan terkait penggunaan kombinasi secukinumab dan methotrexate. Pemberian methotrexate bersamaan dengan agen biologis dapat mencegah atau mengurangi pengembangan antibodi anti-drug dan meningkatkan tingkat respon terhadap pengobatan. Penelitian lanjutan tetap diperlukan dalam menilai mekanisme spesifik terapi kombinasi ini.

Kesimpulan: Terapi kombinasi secukinumab dan methotrexate efektif dalam mengobati manifestasi kulit psoriasis tanpa adanya efek samping bermakna. Kombinasi obat ini berguna dalam mengatasi keterbatasan obat monoterapi, seperti efektifitas yang menurun akibat penggunaan yang berkepanjangan.

Keywords: Methotrexate dan secukinumab psoriasis vulgaris berat

References

  1. Nair PA, Badri T. Psoriasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 11, 2021.
  2. Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016;3(1):79-82. Published 2016 Jun 14. doi:10.14744/nci.2016.16023.
  3. Strober B, Ryan C, Van De Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2019;82(1). p117-122. doi:10.1016/j.jaad.2019.08.026.
  4. Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Moderate Psoriasis: A Proposed Definition. Psoriasis moderada. Propuesta de definición. Actas Dermosifiliogr. 2017. 108(10). p911-917. doi:10.1016/j.ad.2017.07.002.
  5. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285.
  6. Berg SH, Balogh EA, Ghamrawi RI, Feldman SR. A review of secukinumab in psoriasis treatment. Immunotherapy. 2021;13(3):201-216. doi:10.2217/imt-2020-0195.
  7. Jensen P, Skov L, Zachariae C. Systemic combination treatment for psoriasis: A review. Acta Derm Venereol. 2010;90(4):341-349. doi:10.2340/00015555-0905.
  8. Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285-294. doi:10.1007/s40257-015-0131-y.
  9. Tiberio R, Graziola F, Miglino B, Veronese F, Annali G, Savoia P: Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience. Case Rep Dermatol 2019;11(suppl 1):29-37. doi: 10.1159/000501990.
  10. Yeung J, Valbuena V. Successful use of secukinumab in pustular psoriasis. JAAD Case Reports. 2016;2(6):470-472. doi:10.1016/j.jdcr.2016.05.006.
  11. Phung M, Georgakopoulos JR, Ighani A, Giroux L, Yeung J. Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series. JAAD Case Rep. 2018;4(4):310-313. Published 2018 Mar 31. doi:10.1016/j.jdcr.2017.11.006.
  12. Kostaki D, Aquila E, Macaluso L, Mattozzi C, Richetta AG. Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report. Case Rep Dermatol. 2019;11(Suppl 1):17-22. Published 2019 Sep 23. doi:10.1159/000501994.
  13. Thibodeaux Q, Ly K, Reddy V, Smith MP, Liao W. Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Rep. 2019;5(10):928-930. Published 2019 Oct 10. doi:10.1016/j.jdcr.2019.08.015.
  14. Gisondi P, Bellinato F, Bruni M, De Angelis G, Girolomoni G. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol Ther. 2020;33(6):e14281. doi:10.1111/dth.14281.
  15. Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017;18(11):2297. Published 2017 Nov 1. doi:10.3390/ijms18112297.
  16. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis [published correction appears in J Am Acad Dermatol. 2005 Apr;52(4):670. Prodanowich, Srdjan [corrected to Prodanovich, Srdjan]]. J Am Acad Dermatol. 2005;52(2):262-267. doi:10.1016/j.jaad.2004.06.017.
  17. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40. doi:10.1016/j.jaad.2018.06.057.
  18. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-1514. doi:10.1111/jdv.14878.
  19. Haider S, Wahid Z, Najam-Us-Saher, Riaz F. Efficacy of Methotrexate in patients with plaque type psoriasis. Pak J Med Sci. 2014;30(5):1050-1053. doi:10.12669/pjms.305.4451.
  20. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528-537. doi:10.1016/S0140-6736(16)32127-4.
  21. Spindeldreher S, Maillère B, Correia E, et al. Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab [published correction appears in Dermatol Ther (Heidelb). 2018 Mar 17;:]. Dermatol Ther (Heidelb). 2018;8(1):57-68. doi:10.1007/s13555-018-0220-y.
  22. Choquette D, Bessette L, Sauvageau LC, et al. AB0740 Use of secukinumab in patients with psoriatic arthritis. Impacts of combination with methotrexate. In: Abstracts Accepted for Publication. BMJ; 2019:1835.1-1835. doi:10.1136/annrheumdis-2019-eular.3132
  23. Yang EJ, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis (Auckl). 2018;8:75-82. Published 2018 Oct 17. doi:10.2147/PTT.S146004.
  24. Agustina M, Hidayati AN, Hasanatuludhhiyah N. Side Effects of Methotrexate for Psoriasis Therapy. Berk Ilmu Kesehat Kulit dan Kelamin. 2020;32(2):98. doi:10.20473/bikk.v32.2.2020.98-102.

How to Cite

Purbasari, O. K., Widyastuti, N. P. W., & Senak, C. (2021). Efektifitas dan keamanan dari terapi kombinasi methotrexate dan secukinumab pada Psoriasis vulgaris berat: tinjauan sistematis. Intisari Sains Medis, 12(3), 921–926. https://doi.org/10.15562/ism.v12i3.1097
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
189

Total
162

Share

Search Panel

Ovienanda Kristi Purbasari
Google Scholar
Pubmed
ISM Journal

Ni Putu Wina Widyastuti
Google Scholar
Pubmed
ISM Journal

Carolina Senak
Google Scholar
Pubmed
ISM Journal